These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
    Author: Fernández Canigia L, Kaufman S, Lanata L, Vay C, Giovanakis M, Bantar C, Argentinean Tigecycline Surveillance Group.
    Journal: Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645.
    Abstract:
    BACKGROUND: Tigecycline is a new antibiotic currently used in healthcare environments where multidrug resistance is prominent. Because there is a constant potential for resistance to emerge, survey studies are needed. METHODS: Isolates collected in 20 clinical laboratories from 4 states of Argentina between November 2005 and October 2006 were tested using the disk diffusion method as described by the CLSI. RESULTS: A total of 3,182 isolates were assessed. Gram-positive cocci represented 43.4% of the total isolates [Staphylococcus aureus (878), coagulase-negative staphylococci (255), Enterococcus spp. (201), Streptococcus spp. (47)], Enterobacteriaceae 39.6% and Acinetobacter spp. 11.1%. Tigecycline proved equally active against methicillin-resistant and methicillin-susceptible staphylococci, as well as against vancomycin-resistant and vancomycin-susceptible enterococci (100% of susceptibility for all Gram-positive bacteria tested). Tigecycline susceptibility for Enterobacteriaceae, other than Proteeae tribe and Serratia spp., ranged from 88 to 100%, including against strains with resistance to third-generation cephalosporins with phenotype of extended spectrum beta-lactamases (extended spectrum beta-lactamase-positive Escherichia coli 17.7% and extended spectrum beta-lactamase-positive Klebsiella pneumoniae 50.5%). Adopting a resistant breakpoint of 16 mm, 92% of the Acinetobacter isolates were susceptible to tigecycline. CONCLUSION(S): Tigecycline was active against a wide variety of bacterial species, including most of the multidrug-resistant Gram-negative and Gram-positive bacteria. Therefore, it could be a suitable option in the treatment of infections caused by these organisms in hospitalized patients.
    [Abstract] [Full Text] [Related] [New Search]